#USA #Providence #EpiVax #Immunogenicity #Laboratory Expansion

EpiVax Expands Its Laboratory Facilities

EpiVax, Inc., a prominent player in the field of immunogenicity risk assessment, has announced an ambitious expansion of its laboratory facilities located in Providence, Rhode Island. This enhancement more than doubles the laboratory's existing footprint, reflecting the company's response to a growing demand for cutting-edge immunological testing services. The recent upgrades are anticipated to significantly bolster EpiVax's capabilities in evaluating immunogenicity risk through integrated, human-relevant methodologies (NAMs).

With traditional animal models facing scrutiny due to limitations in providing accurate human-relevant data, the introduction of NAMs has emerged as a pivotal component in preclinical immunogenicity risk assessments. Regulatory agencies now endorse these methodologies for evaluating biologics, peptides, generics, and biosimilars, emphasizing that immunogenicity does not merely represent a late-stage clinical observation but rather a continuum that needs to be understood and examined throughout the development process.

EpiVax aims to provide a comprehensive framework that blends computational analysis with in vitro methodologies, allowing for meticulous examination of immune responses. This approach facilitates timely and informed decision-making, aligning closely with the evolving expectations of global regulatory bodies.

The newly expanded laboratory houses best-in-class technology and resources, allowing the team of seasoned experts at EpiVax to conduct assessments using human whole blood, PBMC (peripheral blood mononuclear cells), and specialized antigen-presenting cells like dendritic cells. This arsenal of tools enables modular, scalable assay designs tailored to meet the specific development phase and therapeutic requirements.

EpiVax's comprehensive suite of in vitro assays provides critical insights into innate and adaptive immune responses. The assays employ various techniques, including cellular activation through phenotyping, proliferation, and cytokine secretion readouts, thereby evaluating the potential impact of immune liabilities associated with specific therapies.

This holistic approach to risk assessment allows the company to integrate data from both in silico analyses and in vitro findings, further enhancing the precision and reliability of the results. The use of the ISPRI toolkit exemplifies EpiVax's commitment to employing interdisciplinary methodologies, creating a streamlined workflow that ensures consistency in data collection and analysis.

Historically, EpiVax has demonstrated expertise in applying its unique framework for immunogenicity risk assessment, notably through its PANDA screening methodology tailored for generic peptide products. By combining computational analysis with targeted in vitro assessments, EpiVax can evaluate sequence- and CQA-driven risks effectively, establishing comparability with reference products while navigating the intricacies of regulatory landscapes.

In recent years, the company has successfully supported over 16 global regulatory submissions, underscoring the efficacy of its mechanism-based approach to immunogenicity risk assessment. Vibha Jawa, Ph.D., Chief Scientific Officer of EpiVax, highlighted the company's mission to empower therapeutic developers with human-relevant solutions. This laboratory expansion will further facilitate EpiVax's ability to support its partners in making informed, data-driven decisions throughout the life cycle of their products.

EpiVax is recognized for its profound commitment to managing immunogenicity risk for biopharmaceutical developers. By leveraging deep scientific knowledge combined with forward-thinking strategies, EpiVax enables its partners to streamline their processes, mitigate risks, and prepare for regulatory hurdles. With the expanded laboratory, EpiVax is poised to continue delivering innovative solutions that enhance the safety and efficacy of therapies on the market.

In conclusion, EpiVax stands at the forefront of immunogenicity risk assessment with its cutting-edge laboratory expansion, paving the way for more streamlined and effective therapeutic development processes. By prioritizing human-relevant data, EpiVax not only meets the current needs of healthcare but also anticipates future demands in the ever-evolving landscape of biopharmaceuticals.